Atrial Fibrillation News and Research

RSS
Atrial fibrillation (AF) is the most common arrhythmia. An arrhythmia is a problem with the speed or rhythm of the heartbeat. A disorder in the heart’s electrical system causes AF and other types of arrhythmia. AF occurs when rapid, disorganized electrical signals in the heart’s two upper chambers, called the atria, cause them to contract very fast and irregularly (this is called fibrillation). As a result, blood pools in the atria and isn’t pumped completely into the heart’s two lower chambers, called the ventricles. When this happens, the heart’s upper and lower chambers don’t work together as they should. Often, people who have AF may not even feel symptoms. However, even when not noticed, AF can lead to an increased risk of stroke. In many patients, particularly when the rhythm is extremely rapid, AF can cause chest pain, heart attack, or heart failure. AF may occur rarely or every now and then, or it may become a persistent or permanent heart rhythm lasting for years.
MHA's annual awards recognize outstanding health care leaders, innovative programs

MHA's annual awards recognize outstanding health care leaders, innovative programs

NYU Langone researchers present recent findings at The Heart Rhythm Society 32nd annual sessions

NYU Langone researchers present recent findings at The Heart Rhythm Society 32nd annual sessions

Urgent action needed to avoid preventable strokes in Asia-Pacific region, says new report

Urgent action needed to avoid preventable strokes in Asia-Pacific region, says new report

ESC Heart Failure meeting offers strong scientific programme

ESC Heart Failure meeting offers strong scientific programme

New cardiac resynchronization therapy data in atrial fibrillation presented at Heart Rhythm 2011

New cardiac resynchronization therapy data in atrial fibrillation presented at Heart Rhythm 2011

New cardiac genetic testing guidelines for health care professionals

New cardiac genetic testing guidelines for health care professionals

Biosense Webster enters new agreement with Stereotaxis to deploy Odyssey products

Biosense Webster enters new agreement with Stereotaxis to deploy Odyssey products

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Boston Scientific reports first use in Europe of Blazer Open-Irrigated Catheter

Boston Scientific reports first use in Europe of Blazer Open-Irrigated Catheter

First cryoablation procedure using new mapping catheter performed at Baylor Heart and Vascular Hospital

First cryoablation procedure using new mapping catheter performed at Baylor Heart and Vascular Hospital

FDA approves Achieve Mapping Catheter for use in first patient procedure

FDA approves Achieve Mapping Catheter for use in first patient procedure

Bristol-Myers Squibb first quarter net sales increase 5% to $3.3 billion

Bristol-Myers Squibb first quarter net sales increase 5% to $3.3 billion

Stereotaxis launches Stereotaxis Epoch solution for electrophysiology lab

Stereotaxis launches Stereotaxis Epoch solution for electrophysiology lab

ACC/AHA release consensus document to help clinicians reduce risk of hypertension in older adults

ACC/AHA release consensus document to help clinicians reduce risk of hypertension in older adults

Daiichi Sankyo's LIXIANA receives Japanese marketing approval

Daiichi Sankyo's LIXIANA receives Japanese marketing approval

St. Jude Medical first quarter net sales increases 9% to $1.376 billion

St. Jude Medical first quarter net sales increases 9% to $1.376 billion

New research: 56% of Canadians with AF do not fear having fatal stroke

New research: 56% of Canadians with AF do not fear having fatal stroke

ARCA biopharma to sell $3 million of common stock and warrants in registered direct offering

ARCA biopharma to sell $3 million of common stock and warrants in registered direct offering

Boehringer Ingelheim's dabigatran etexilate receives positive opinion from EMA committee

Boehringer Ingelheim's dabigatran etexilate receives positive opinion from EMA committee

J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism

J&JPRD announces rivaroxaban Phase 3 trial results against venous thromboembolism

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.